• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

    5/8/25 2:36:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAK alert in real time by email
    • Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024
    • Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings
    • Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated
    • FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation
    • Proposed Dividend Increase from JPY 196 to JPY 200

    Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management.

    Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rusfertide in Oncology in March 2025, the company anticipates a further two Phase 3 readouts in core therapeutic areas this fiscal year.

    FY2025 Management Guidance at CER reflects residual carry-over of VYVANSE® generic impact, continued efficiency savings and investment in R&D and launch preparation for Takeda's late-stage pipeline.

    Takeda chief executive officer, Christophe Weber, commented:

    "Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our Growth & Launch Products portfolio and the ability of our multi-year efficiency program to deliver meaningful cost savings.

    "FY2025 will be a pivotal year as we invest in launch readiness for the late-stage pipeline, which will contribute to our broadly flat Core Operating Profit outlook for FY2025 but will be key to achieving Takeda's long-term growth potential."

    Takeda chief financial officer, Milano Furuta, commented:

    "Takeda's success in delivering revenue and Core Operating Profit growth in FY2024 and our outlook for broadly flat revenue and profit in FY2025, demonstrates our ability to manage through one of the largest generic impacts on our business in Takeda's history while progressing a highly promising late-stage pipeline. Our performance and outlook speak to the strength of our Growth & Launch Products, our innovative pipeline and the resilience of our organization as a whole.

    "Takeda is now at an inflection point, with multiple anticipated Phase 3 data readouts this fiscal year, and I'm excited about our growth trajectory."

    FINANCIAL HIGHLIGHTS for FY2024 Ended March 31, 2025

    (Billion yen, except percentages and per share amounts)

     

    FY2024

    FY2023

    vs. PRIOR YEAR

    (Actual % change)

    Revenue

    4,581.6

    4,263.8

    +7.5%

    Operating Profit

    342.6

    214.1

    +60.0%

    Net Profit

    107.9

    144.1

    -25.1%

    EPS (Yen)

    68

    92

    -25.8%

    Operating Cash Flow

    1,057.2

    716.3

    +47.6%

    Adjusted Free Cash Flow (Non-IFRS)

    769.0

    283.4

    +171.3%

    Core (Non-IFRS)

    (Billion yen, except percentages and per share amounts)

     

    FY2024

    FY2023

    vs. PRIOR YEAR

    (Actual % change)

    vs. PRIOR YEAR

    (CER % change)

    Revenue

    4,579.8

    4,263.8

    +7.4%

    +2.8%

    Operating Profit

    1,162.6

    1,054.9

    +10.2%

    +4.9%

    Margin

    25.4%

    24.7%

    +0.6pp

    ―

    Net Profit

    775.6

    756.8

    +2.5%

    -3.4%

    EPS (Yen)

    491

    484

    +1.5%

    -4.3%

    FY2025 Outlook

    (Billion yen, except percentages and per share amounts)

    Item

    FY2025 FORECAST

    FY2025

    MANAGEMENT

    GUIDANCE

    Core Change at CER

    (Non-IFRS)

    Revenue

    4,530.0

    ---

    Core Revenue (Non-IFRS)

    4,530.0

    Broadly flat

    Operating Profit

    475.0

    ---

    Core Operating Profit (Non-IFRS)

    1,140.0

    Broadly flat

    Net Profit

    228.0

    ---

    EPS (Yen)

    145

    ---

    Core EPS (Yen) (Non-IFRS)

    485

    Broadly flat

    Adjusted Free Cash Flow (Non-IFRS)

    750.0-850.0

    ---

    Annual Dividend per Share (Yen)

    200

    ---

    Additional Information About Takeda's FY2024 Results

    For more details about Takeda's FY2024 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda's FY2024 Q4 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/)

    About Takeda

    Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

    Important Notice

    For the purposes of this notice, "press release" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

    The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

    The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

    Forward-Looking Statements

    This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

    Financial information and Non-IFRS Measures

    Takeda's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

    This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate ("CER") change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda's management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda's non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as "reported" measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2024 investor presentation (available at www.takeda.com/investors). Beginning in the quarter ended June 30, 2024, Takeda (i) changed its methodology for CER adjustments to results of subsidiaries in hyperinflation countries to present those results in a manner consistent with IAS 29, Financial Reporting in Hyperinflation Economies, (ii) re-named Free Cash Flow as previously calculated as "Adjusted Free Cash Flow" (with "Free Cash Flow" to be reported as Operating Cash Flow less Property, Plant and Equipment), and (iii) re-named Net Debt as previously calculated as "Adjusted Net Debt" (with "Net Debt" to be reported as the book value of bonds and loans less cash and cash equivalents).

    Medical information

    This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

    Please refer to slide 5 of Takeda's FY2024 Q4 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/) for the definition of Growth & Launch Products.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250427084429/en/

    Investor Relations

    Christopher O'Reilly

    [email protected]

    +81 (0) 90-6481-3412

    Media Relations

    Brendan Jennings

    [email protected]

    +81 (0) 80-2705-8259

    (Outside Japan business hours)

    [email protected]

    Get the next $TAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TAK

    DatePrice TargetRatingAnalyst
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    3/16/2023$20.00Neutral → Buy
    BofA Securities
    7/19/2022$21.00 → $24.00Market Perform → Outperform
    Cowen
    10/7/2021Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

      Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o

      5/8/25 2:36:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

      -New Technology Optimizes Plasma Collection Resulting in Efficiency Gains -Helps Strengthen Plasma Supply Used to Produce Lifesaving and Life-Sustaining Medicines BioLife Plasma Services, part of Takeda (NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the end of December 2025. This press release features multimedia. View the full relea

      5/5/25 8:00:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

      Annual Grants Deepen Takeda's Commitment to Improving Health Through Community-Based Programs Takeda Publishes U.S. Community Impact Report Highlighting Progress toward a More Equitable Health Ecosystem See the full release at Takeda.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250430215346/en/ Media Contact: Takeda Media Relations [email protected]

      4/30/25 8:05:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Leadership Updates

    Live Leadership Updates

    See more
    • Vatroslav Mateljic Appointed General Manager of Takeda Canada

      Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sectorTORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Mr. Mateljic has held a number of executive leadership roles in sales, marketing and country management over his 25-year career in the pharmaceutical industry.  Mos

      9/16/24 8:39:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

      Takeda (TYO:4502, NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave

      3/26/24 7:07:00 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

      2024 Award Celebrates Outstanding Research in Cancer Immunology Winners Discovered Novel Connections Between the Immune System and Cancer Recipients Each Receive Unrestricted USD 200,000 Awards Takeda ((TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205723166/en/ The 2024 Senior Scientist winner is Robert D. Schre

      12/5/23 8:00:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 840,500 shares (Amendment)

      3/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      5/9/22 6:10:39 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 500,000 shares

      3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      4/29/22 6:02:17 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Takeda Pharmaceutical Co Ltd

      3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      10/21/21 8:40:37 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Financials

    Live finance-specific insights

    See more
    • Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

      Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o

      5/8/25 2:36:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

      Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch Products (+14.6% at CER) Core Operating Profit Increase of +10.1% at CER; Core OP Margin Climbs to 28.5% Reported Operating Profit +86.3% at AER Reflects Lower Impairment of Intangible Assets Compared to FY2023 Raises Adjusted Free Cash Flow Forecast Range by JPY 150.0 billion to JPY550.0 - JPY650.0 billion Announces Share Buyback of up to JPY 100.0 billion Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth &

      1/30/25 1:35:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

      SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

      2/6/24 9:36:34 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

      SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

      2/5/24 6:24:58 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

      SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

      2/7/23 2:10:49 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Takeda Pharma upgraded by Morgan Stanley

      Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight

      4/2/25 8:46:19 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Pharma upgraded by BofA Securities with a new price target

      BofA Securities upgraded Takeda Pharma from Neutral to Buy and set a new price target of $20.00

      3/16/23 7:24:52 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Pharma upgraded by Cowen with a new price target

      Cowen upgraded Takeda Pharma from Market Perform to Outperform and set a new price target of $24.00 from $21.00 previously

      7/19/22 7:32:25 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    SEC Filings

    See more
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      5/8/25 6:19:03 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      5/8/25 6:14:51 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      4/22/25 6:08:45 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care